JAN 22, 2020 12:21 PM PST

How the VISTA molecule affects immune responses

A new study describes how a molecule named VISTA has been impeding immune responses in cancer therapies. By turning this molecule “off,” researchers from Dartmouth Hitchcock's Norris Cotton Cancer Center have figured out how to improve immune responses in patients receiving anticancer treatments. The study was published under the title, "VISTA, a checkpoint regulator of naïve T-cell quiescence and tolerance in the periphery” in the journal Science.

"We have learned that keeping your immune system quiet is a challenging and very active process," says lead investigator Randolph Noelle, PhD. "VISTA mediates immune system function and its loss can result in the development of unwanted immune responses. But VISTA may also be a valuable target in regulating the immune response in cancer and autoimmunity."

VISTA is what scientists call a negative checkpoint regulator. That means that it tempers the immune system in order to stop the activation of self-antigens like cancer cells. "Like other negative checkpoint regulators, blocking VISTA in cancer may enhance the host's ability to make protective tumor-specific immune responses," says Noelle.

Noelle and the team of researchers have been working on understanding the role of the VISTA molecule, which stands for V-domain Ig suppressor of T-cell activation, for almost ten years. Finally, as the authors write in the study, they have something to show for all their hard work:

“Therapeutic targeting of VISTA using an agonistic antibody in mice curbed the development of graft-versus-host disease and promoted the death of naïve T cells abnormally activated by self-antigen. VISTA thus represents a distinctive immunoregulatory molecule that controls naïve T cell function by maintaining quiescence and peripheral tolerance.”

New research aims to understand VISTA's role in the immune system. Photo: Pixabay

The researchers hope to use this finding to run clinical trials to determine if their research can be used outside of mice in human patients with cancer. As Science Daily reports, if this is possible, “this antibody may be valuable in the development of drugs and vaccines to provide therapeutic response to cancer and cancer cures.”

Sources: Science, Science Daily

About the Author
Bachelor's (BA/BS/Other)
Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
SEP 30, 2022
Cancer
Sedentary Lifestyle Linked to Breast Cancer Risk
Sedentary Lifestyle Linked to Breast Cancer Risk
Experts have recognized that active lifestyles favor lower breast cancer risk.  However, despite this long-standing ...
OCT 28, 2022
Cancer
Pancreatic Tumor Growth and Metastasis Inhibited
Pancreatic Tumor Growth and Metastasis Inhibited
Pancreatic ductal adenocarcinoma (PDAC), a highly aggressive type of pancreatic cancer, has a very poor prognosis due, a ...
NOV 14, 2022
Cancer
Breast Cancer Vaccine Shows Promise as it Enters Phase 2 Trial
Breast Cancer Vaccine Shows Promise as it Enters Phase 2 Trial
About 20% of breast cancers exhibit elevated levels of a protein known as HER2.  You may have heard the classifier ...
NOV 29, 2022
Drug Discovery & Development
Chemotherapy May Increase Disease Susceptibility for Two Generations
Chemotherapy May Increase Disease Susceptibility for Two Generations
A common chemotherapy drug may make future generations more susceptible to disease. The corresponding study was publishe ...
DEC 10, 2022
Cell & Molecular Biology
Using AI to Build a Better Immunotherapy
Using AI to Build a Better Immunotherapy
T cells that are used in immunotherapy have to be programmed to efficiently destroy cancer cells. Researchers have now u ...
DEC 26, 2022
Immunology
An Antibody Successfully Treats Over 70% of Multiple Myeloma Patients in Trial
An Antibody Successfully Treats Over 70% of Multiple Myeloma Patients in Trial
Almost every patient who gets myeloma and is treated with a standard therapy also experiences relapse. But researchers h ...
Loading Comments...